PAR-27-090-Full-Announcement.html

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Cancer Institute (NCI)

Tribal Health Research Office (THRO)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

Funding Opportunity Title

Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (R01 Clinical Trial Optional)

Activity Code

R01 Research Project Grant

Announcement Type

New

Related Notices

Check for any recent Notices of NIH Policy Changes that may impact application requirements.

Funding Opportunity Number (FON)

PAR-27-090

Companion Funding Opportunity

None

Number of Applications

See Part 2, Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.866, 93.242, 93.393, 93.307, 93.853, 93.865, 93.361

Funding Opportunity Purpose

The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications proposing research on palliative care across the lifespan for persons with serious illnesses and/or their care partners relevant to the missions of participating NIH Institutes, Centers, and Offices (ICOs), including projects focused on palliative care access, use, and quality. Applications may propose hypothesis-driven, milestone-defined palliative care traditional efficacy (Stage II), real-world efficacy (Stage III), effectiveness (Stage IV), and/or dissemination and implementation (Stage V) clinical trials in alignment with the NIH Stage Model (Stages II-V) and relevant Institute or Center policies. Applications may propose non-clinical trial palliative care research, such as health services research, methodologic research, natural experiments, or observational studies. Recipients will become members of the research community facilitated by the NIH-funded Advancing the Science of Palliative Care Across the Lifespan (ASCENT) Consortium.

NOTE: This NOFO is not appropriate for applications proposing new intervention generation, refinement, modification, adaptation, and/or pilot testing (Stage I of the NIH Stage Model) clinical trial research. The intervention(s) to be tested must be in a developed and testable form, with Stage I activities already completed and demonstrated.

Funding Opportunity Goal(s)

To seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

Key Dates

Posted Date

October 14, 2026

Open Date (Earliest Submission Date)

January 05, 2027

The following table includes NIH standard due dates marked with an asterisk.

February 05, 2027 *

March 05, 2027 *

Not Applicable

December 2027

June 05, 2027 *

July 05, 2027 *

Not Applicable

April 2028

October 05, 2027 *

November 05, 2027 *

Not Applicable

July 2028

February 05, 2028 *

March 05, 2028 *

Not Applicable

December 2028

June 05, 2028 *

July 05, 2028 *

Not Applicable

April 2029

October 05, 2028 *

November 05, 2028 *

Not Applicable

July 2029

February 05, 2029 *

March 05, 2029 *

Not Applicable

December 2029

June 05, 2029 *

July 05, 2029 *

Not Applicable

April 2030

October 05, 2029 *

November 05, 2029 *

Not Applicable

July 2030

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Due Dates for E.O. 12372

Not Applicable

Expiration Date

November 06, 2029

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

Table of Contents

Part 1. Overview Information Key Dates Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII. Other Information

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Background Palliative care is holistic interdisciplinary care focused on improving quality of life for persons with serious illness across the lifespan and their families and care partners. Serious illness includes conditions such as cancer, heart disease, chronic kidney disease, and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), for which palliative care is associated with improved care quality and, in some cases, length of life. The core elements of palliative care include:

Palliative care may occur alongside other care intended to cure or delay progression of underlying disease and may be initiated as early as the time of diagnosis. Palliative care teams can include members from a range of medical and surgical specialties (e.g., internal medicine, pediatrics, oncologic surgery, psychiatry, neurology) and disciplines (e.g., physician assistants, nurse practitioners, social workers, chaplains).

Toward the final months or weeks of life, an individual may elect to discontinue curative treatment while maintaining focus on quality of life and relief of suffering. This focused care may be provided in hospice settings or via hospice services in the home when a patient has an expected survival of 6 months or less. Hospice care is a subset of palliative care delivered at the end of life. In this NOFO, the term "palliative care" includes, but is not limited to, advance care planning, end-of-life care, and hospice care.

Access to reliable high-quality palliative care for a range of serious illnesses across the life span is a growing public health priority. It is estimated that about 12 million adults and hundreds of thousands of children are living in the U.S. with serious illnesses, and many are living longer with disease. The problem of limited access to palliative care is worsened by the projected increase in the population of older adults, the majority of whom live with multiple chronic conditions.

Purpose and Scope The purpose of this NOFO is to invite R01 applications proposing research on palliative care across the lifespan for persons with serious illnesses and/or their care partners relevant to the missions of participating NIH Institutes, Centers, and Offices (ICOs), including projects focused on palliative care access, use, and quality. Applications may propose hypothesis-driven, milestone-defined palliative care efficacy, effectiveness, and/or implementation and dissemination clinical trials in alignment with the NIH Stage Model (Stages II-V) and relevant Institute or Center policies. Applications may propose non-clinical trial palliative care research, such as health services research, methodologic research, natural experiments, or observational studies. Recipients will become members of the research community facilitated by the NIH-funded ASCENT Consortium.

Applications with and without proposed clinical trials may be submitted to this NOFO. Refer to the NIH definition of a clinical trial to determine whether your application includes a clinical trial.

Research areas of interest include, but are not limited to:

Scope of this NOFO: Clinical Trials Applications The palliative care literature underscores the need for rigorous, well-powered, replicable clinical trial research addressing issues of intervention fidelity, efficacy, and potential intervention mechanisms, prior to dissemination and implementation on a wide scale. Applicants are encouraged to review and reference palliative care intervention research priorities from the existing literature and consensus documents and intervention research priorities identified by the ASCENT Consortium, if available.

NIH will accept applications to this NOFO that propose rigorous efficacy, effectiveness, and/or implementation intervention research (i.e., Stages II – V of the NIH Stage Model), for which a rigorous planning and feasibility demonstration phase (i.e., Stage I) has already been completed. Applicants seeking to propose a Stage I clinical trial may wish to visit the ASCENT Consortium for pilot funding opportunities.

The NIH Stage Model The NIH Stage Model offers a framework to:

This NOFO solicits mechanism-focused palliative care intervention development research at Stages II through V of the NIH Stage Model, which has the ultimate goal of creating efficacious, implementable interventions defined by their principles.

Stage II – V research invited via this NOFO is described below:

Stage 1 intervention development research as defined below is not appropriate for this NOFO.

Stage I: Creation, Adaptation, Modification & Pilot-Testing (CAMP) of the full intervention, including procedures for teaching providers to deliver the intervention correctly:

Clinical trial conduct is expected to implement the scientific and operational tools developed prior to the research proposed in this application or during a planning phase of the proposed work. Applications proposing Stage I work to develop a new behavioral intervention or to adapt an existing behavioral intervention, to establish acceptability and feasibility of the intervention, and to develop interventionist training and supervision materials de novo are not within scope of this NOFO.

In addition to clearly aligning intervention research questions with study methods (and stages of intervention development research), this NOFO expects tests of hypothesized intervention mechanisms of action and heterogeneity of intervention effects. Tests of hypothesized mechanisms of action are often (but not only) tested via mediation analyses, and heterogeneity of intervention effects are often (but not only) tested as moderation effects. For heterogeneity of intervention effects analyses, this includes the identification of specific individuals who are more or less likely to benefit from the intervention(s) based on genetic profiles, individual differences, behavioral factors, sociocultural, and/or clinical and demographic factors. Heterogeneity of intervention effects may elucidate different causal mechanisms at work for different populations or individuals.

Clinical trials that propose the testing of pharmacologic agents or devices that have a therapeutic indication for symptom reduction/control may be within scope, however the agent or device should not be at a stage of therapeutic development that requires an Investigational New Drug (IND) application. In addition, a trial testing a pharmacologic agent or device is expected to have pilot data and/or proof-of-principle data that confirm a direct mechanistic link between the agent or device and improved symptom outcomes, and should also have mitigation of the targeted symptom(s) as its primary endpoint. Trials designed to primarily address the dose, schedule, delivery route, safety, or side effects of the pharmacologic agent or device are not within scope of this NOFO.

Applicants are strongly encouraged to discuss proposed clinical trials with an NIH scientific contact prior to applying.

Before commencing, the clinical trial will be expected to meet all applicable NIH and Office of Human Research Protections (OHRP) policy requirements, including the NIH policy for Single IRB for Multi-Site or Cooperative Research | Grants & Funding, if applicable, and have NIH and IRB approval. Less than satisfactory progress towards clinical trial milestones may lead to phasing out the award.

Scope of this NOFO: Non-Clinical Trials Applications This NOFO encompasses non-clinical trial research projects focused on palliative care or aspects of palliative care as defined in the Background section. Applicants are encouraged to review and reference research priorities from the existing literature and consensus documents and research priorities identified by the ASCENT Consortium.

Proposed study designs may include, but are not limited to:

Applications Not Responsive to this NOFO The following types of studies are not responsive to this NOFO. Applications proposing such studies will be considered non-responsive and will not be reviewed or considered for funding.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

Application Types Allowed

New

Renewal

Resubmission

Revision

The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Optional: Accepting applications that either propose or do not propose clinical trial(s).

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award Project Period

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Nonprofits Other Than Institutions of Higher Education

For-Profit Organizations

Local Governments

Federal Governments

Eligible Agencies of the Federal Government

U.S. Territory or Possession

Other

Independent School Districts

Public Housing Authorities/Indian Housing Authorities

Native American Tribal Organizations (other than Federally recognized tribal governments)

Faith-based or Community-based Organizations

Regional Organizations

Non-domestic (non-U.S.) Entities (Foreign Organizations)

Foreign Organizations/International Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Required Registrations

Applicant Organizations Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information.

System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.

Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply-Application Guide.

2. Cost Sharing This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.

A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations All page limitations described in the How to Apply- Application Guide and the Table of Page Limits must be followed.

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply- Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations All instructions in the How to Apply- Application Guide must be followed.

SF424(R&R) Other Project Information

SF424(R&R) Senior/Key Person Profile

R&R or Modular Budget

Applications must budget for required interactions with the NIH-funded ASCENT Consortium, as defined below in the PHS 398 Research Plan section. Applications must budget for any optional ASCENT Consortium services or interactions the applicant proposes to use. Applicants must contact the ASCENT Consortium prior to applying to discuss planned interactions and their costs.

R&R Subaward Budget

PHS 398 Cover Page Supplement

PHS 398 Research Plan All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Applicants must contact the ASCENT Consortium prior to application submission to discuss the required interactions.

Applicants may wish to propose using additional, optional services offered by the ASCENT Consortium cores and should discuss these with ASCENT Consortium staff prior to applying to this NOFO.

For applications proposing a Clinical Trial Before commencing, the clinical trial must meet all applicable NIH and Office of Human Research Protections (OHRP) policy requirements, including the NIH policy for Single IRB for Multi-Site or Cooperative Research | Grants & Funding, if applicable, and have NIH and IRB approval.

The research strategy must:

Milestone Plan All applications proposing a clinical trial must include a Milestone Plan.

Planning Phase: Milestones must include, at a minimum:

Active Trial Phase: Milestones must include, at a minimum:

If applicable to the proposed clinical trial, the research strategy should include a Co-Enrollment Plan If applicable to the proposed clinical trial, applicants must describe any planned or reasonably anticipated co-enrollment for participants. Information should include but is not limited to:

Trials testing a pharmacologic agent or device Trials testing a pharmacologic agent or device must have pilot data and/or proof-of-principle data that confirm a direct mechanistic link between the agent or device and improved symptom outcomes. The trial of a pharmacologic agent or a device must also have mitigation of the targeted symptom(s) as its primary endpoint.

For applications proposing use of CMS data linkages:

The NIA Data Linkage Program (LINKAGE) is available for use by the NIH grantee community. The purpose of the Program is to link NIH-funded study data with existing datasets from Centers for Medicare & Medicaid Services (CMS) and other sources and establish a virtual environment to support data accessibility and sharing. LINKAGE reduces resource cost and time barriers while promoting data access for researchers. The program provides three primary services including a linkage service, technical assistance, and a cloud-based platform (enclave) for investigator use.

The program has successfully linked CMS claims data to more than 30 studies including multi-disciplinary NIH-funded studies that focus on caregiving, disability, mortality, dementia diagnosis and more. The enclave offers Medicare Parts A, B, C and D data, Medicare enrollment and assessment data, and Medicaid data.

Applications proposing to link CMS data must:

Applicants must articulate a plan to complete the following steps within the first 150 days of their award and provide a milestone (Gantt) chart in their grant application. Applications must describe how the following steps will be incorporated in the research plan and timeline:

For more information, please contact support@linkagesupport.zendesk.com with questions.

Letters of Support: The Research Plan must include a letter of support from the ASCENT Consortium. Applications proposing to leverage NIH-supported trial networks (e.g., NCI Community Oncology Research Program (NCORP), NIH Pragmatic Trials Collaboratory, IMPACT Collaboratory) must demonstrate that pre-application approvals to use network resources have been secured.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s):

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

PHS Human Subjects and Clinical Trials Information When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply- Application Guide, with the following additional instructions:

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

Section 2 - Study Population Characteristics

2.5 Recruitment and Retention Plan

Without duplicating information in the attachments to the PHS Human Subjects and Clinical Trials Information form, applications in response to this funding opportunity must provide further rationale supporting eligibility criteria and study population characteristics. Applicants should propose innovative and proactive recruitment strategies as applicable and justified by the scientific goals. Applicants should ensure that they address the populations appropriate and relevant to the proposed research and scientific goals. Recruitment and retention plans should demonstrate an understanding of the participant burden involved in research participation and strategies for minimizing this burden, as well as leveraging community partners and outreach efforts.

The recruitment and retention plan must:

In addition, applicants should provide rationale supporting eligibility criteria and study population characteristics that are representative of the population affected by the disease/condition as well as other populations relevant to the proposed research and scientific goals.

Where applicable, study teams should also demonstrate that they have critically evaluated whether eligibility criteria from an earlier phase trial should be carried forward into a later phase trial. Further rationale supporting eligibility criteria and study population should explain how the rationale for selected eligibility criteria justifies the level of restriction in the study compared to clinical practice

Delayed Onset Study Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply- Application Guide must be followed.

PHS Assignment Request Form

Foreign Organizations Foreign (non-U.S.) organizations must follow policies described in the NIH Grants Policy Statement, and procedures for foreign organizations described throughout the How to Apply- Application Guide.

3. Unique Entity Identifier and System for Award Management (SAM) See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the How to Apply-Application Guide.

5. Intergovernmental Review (E.O. 12372) This initiative is not subject to intergovernmental review.

6. Funding Restrictions All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the How to Apply – Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply – Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Mandatory Disclosure

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.35.

Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov.

Post Submission Materials Applicants are required to follow the instructions for post-submission materials, as described in the policy

Section V. Application Review Information

1. Criteria Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following scored review criteria and additional review criteria (as applicable for the project proposed).